140,000 is in-line with the stats I posted the other day. RP stayed that CCR5 was over expressed in approximately 50% of colon cancer (along with breast, prostate and pancreatic and other metastatic cancers), so I believe that all of these over expressed CCR5 cancers would be the target patients for leronlimab (pending positive clinical results).